Temporarily Under Construction Due to Exclusive Licensing of Novel Oncology Drugs with Dual Mechanism for the Inhibition of cMyc and Topo 1.

February 2020

For more information click press release below:
Gibson Oncology Obtains Exclusive Commercial Rights to Novel Anti-Cancer Drugs That Inhibit the “Undruggable” cMyc Oncogene, a Key Driver for the Majority of Cancers